MEI Pharma, Inc. – LSE:0JW9.L
MEI Pharma stock price today
MEI Pharma stock price monthly change
MEI Pharma stock price quarterly change
MEI Pharma stock price yearly change
MEI Pharma key metrics
Market Cap | 16.37M |
Enterprise value | 28.62M |
P/E | 0.73 |
EV/Sales | 0.42 |
EV/EBITDA | 1.25 |
Price/Sales | 0.28 |
Price/Book | 0.37 |
PEG ratio | 0.01 |
EPS | -7.49 |
Revenue | N/A |
EBITDA | -53.06M |
Income | -49.91M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 39.18% |
Oper. margin | 33.62% |
Gross margin | 98.36% |
EBIT margin | 33.62% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMEI Pharma stock price history
MEI Pharma stock forecast
MEI Pharma financial statements
| Jun 2022 | 11.41M | -16.26M | -142.54% |
|---|---|---|---|
| Mar 2023 | 5.89M | -14.48M | -245.76% |
| Jun 2023 | 1.45M | -10.02M | -688.33% |
| Mar 2024 | 0 | -9.12M |
| 2028 | 25M | -10.39M | -41.58% |
|---|
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 0% |
|---|
| 2020 | |
|---|---|
| 2021 | |
| 2022 | |
| 2023 | |
| 2024 | 61.4% |
| Dec 2022 | 147599000 | 99.22M | 67.23% |
|---|---|---|---|
| Mar 2023 | 134187000 | 99.83M | 74.4% |
| Jun 2023 | 120809000 | 96.18M | 79.62% |
| Mar 2024 | 71260000 | 20.23M | 28.39% |
| Jun 2022 | -15.50M | 20.11M | 20K |
|---|---|---|---|
| Mar 2023 | -12.13M | 10.02M | 0 |
| Jun 2023 | -11.30M | 19.39M | 0 |
| Mar 2024 | -2.92M | 122K | 0 |
MEI Pharma alternative data
| Aug 2023 | 102 |
|---|---|
| Sep 2023 | 102 |
| Oct 2023 | 102 |
| Nov 2023 | 46 |
| Dec 2023 | 46 |
| Jan 2024 | 46 |
| Feb 2024 | 46 |
| Mar 2024 | 46 |
| Apr 2024 | 46 |
| May 2024 | 46 |
| Jun 2024 | 46 |
| Jul 2024 | 46 |
MEI Pharma other data
| Patent |
|---|
Application Filling date: 2 May 2022 Issue date: 25 Aug 2022 |
Application Filling date: 1 Mar 2022 Issue date: 23 Jun 2022 |
Grant Utility: Combination therapy Filling date: 14 Aug 2018 Issue date: 7 Jun 2022 |
Grant Utility: Combination therapy Filling date: 22 May 2018 Issue date: 19 Apr 2022 |
Application Filling date: 26 Nov 2019 Issue date: 20 Jan 2022 |
Application Filling date: 5 Mar 2021 Issue date: 25 Nov 2021 |
Application Filling date: 13 Aug 2019 Issue date: 30 Sep 2021 |
Application Filling date: 16 Mar 2021 Issue date: 2 Sep 2021 |
Application Filling date: 13 Aug 2019 Issue date: 1 Jul 2021 |
Application Filling date: 13 Aug 2019 Issue date: 3 Jun 2021 |
| Insider | Compensation |
|---|---|
| Dr. Daniel P. Gold (1954) Pres, Chief Executive Officer & Director | $1,140,000 |
Mr. David M. Urso B.A., Esq., J.D. (1964) Chief Operating Officer & Gen. Counsel | $718,750 |
Mr. Brian G. Drazba B.A., CPA, CPA (1961) Chief Financial Officer & Sec. | $603,000 |
| Dr. Robert D. Mass (1954) Chief Medical Officer | $294,590 |
Dr. Karen E. Potts Ph.D. Senior Vice President of Regulatory Affairs | |
Dr. Richard G. Ghalie Senior Vice President of Clinical Devel. | |
Mr. David A. Walsey J.D., L.L.M. Vice President of IR & Corporation Communications | |
Mr. Brian T. Powl Senior Vice President of Marketing | |
Dr. Ofir Moreno Senior Vice President of Pharmaceutical Sciences |
-
What's the price of MEI Pharma stock today?
One share of MEI Pharma stock can currently be purchased for approximately $2.61.
-
When is MEI Pharma's next earnings date?
Unfortunately, MEI Pharma's (0JW9.L) next earnings date is currently unknown.
-
Does MEI Pharma pay dividends?
Yes, MEI Pharma pays dividends and its trailing 12-month yield is 60.34% with 0% payout ratio. The last MEI Pharma stock dividend of undefined was paid on 7 Sep 2025.
-
How much money does MEI Pharma make?
MEI Pharma has a market capitalization of 16.37M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 33.76% to 65.3M US dollars.
-
What is MEI Pharma's stock symbol?
MEI Pharma, Inc. is traded on the LSE under the ticker symbol "0JW9.L".
-
What is MEI Pharma's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of MEI Pharma?
Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the following people:
- Dr. Daniel P. Gold Pres, Chief Executive Officer & Director(age: 71, pay: $1,140,000)
- Mr. David M. Urso B.A., Esq., J.D. Chief Operating Officer & Gen. Counsel(age: 61, pay: $718,750)
- Mr. Brian G. Drazba B.A., CPA, CPA Chief Financial Officer & Sec.(age: 64, pay: $603,000)
- Dr. Robert D. Mass Chief Medical Officer(age: 71, pay: $294,590)
- Dr. Karen E. Potts Ph.D. Senior Vice President of Regulatory Affairs
- Dr. Richard G. Ghalie Senior Vice President of Clinical Devel.
- Mr. David A. Walsey J.D., L.L.M. Vice President of IR & Corporation Communications
- Mr. Brian T. Powl Senior Vice President of Marketing
- Dr. Ofir Moreno Senior Vice President of Pharmaceutical Sciences
-
How many employees does MEI Pharma have?
As Jul 2024, MEI Pharma employs 46 workers.
-
When MEI Pharma went public?
MEI Pharma, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is MEI Pharma's official website?
The official website for MEI Pharma is meipharma.com.
-
Where are MEI Pharma's headquarters?
MEI Pharma is headquartered at 11455 El Camino Real, San Diego, CA.
-
How can i contact MEI Pharma?
MEI Pharma's mailing address is 11455 El Camino Real, San Diego, CA and company can be reached via phone at 858 369 7100.
MEI Pharma company profile:
MEI Pharma, Inc.
meipharma.comLSE
28
Medical - Pharmaceuticals
Healthcare
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
San Diego, CA 92130
:
ISIN: US55279B3015
CUSIP: 55279B301
